Takeda Oncology
Annie Huang serves as the Director of Market Access Strategy at Takeda Oncology since May 2020, leading market access initiatives for the Multiple Myeloma and Leukemia franchise, including launch planning and cross-functional collaboration. Prior to this role, Annie held various positions at Dermira, Inc. where achievements included launching Qbrexza™ and creating innovative marketing tools. Experience at Amgen encompassed management of sales teams and successful launches of key products, while earlier roles at Pfizer and as Assistant Director of Admission at Newbury College provided a strong foundation in sales and recruitment. Annie holds an MBA in Marketing and International Business from Zicklin School of Business and a BA in Communications and Education from Boston College. Recognition includes speaking engagements and leadership program involvement.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.